Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 2:12:1431423.
doi: 10.3389/fcell.2024.1431423. eCollection 2024.

Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway

Jiageng Guo  1   2   3 , Xinya Jiang  4 , Jing Lian  1   2   3 , Huaying Li  1   2   3 , Fan Zhang  1   2   3 , Jinling Xie  1   2   3 , Jiagang Deng  1   2   3 , Xiaotao Hou  1   2   3 , Zhengcai Du  1   2   3 , Erwei Hao  1   2   3
Affiliations
Review

Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway

Jiageng Guo et al. Front Cell Dev Biol. .

Abstract

The PI3K/AKT/GSK-3β signaling pathway plays a pivotal role in numerous physiological and pathological processes, including cell proliferation, apoptosis, differentiation, and metabolic regulation. Aberrant activation of the PI3K/AKT pathway is intricately linked to development of tumor. GSK-3β, belonging to the serine/threonine protein kinase family, is crucial in the pathogenesis of liver cancer. As a key rate-limiting enzyme in the glucose metabolism pathway, GSK-3β significantly impacts the growth, proliferation, metastasis, and apoptosis of liver cancer cells. It is also implicated in chemotherapy resistance. Elevated expression of GSK-3β diminishes the sensitivity of liver cancer cells to chemotherapeutic agents, thereby playing a substantial role in the development of drug resistance. Consequently, targeting of GSK-3β, particularly within the PI3K/AKT signaling pathway, is regarded as a promising therapeutic strategy for liver cancer. The precise identification and subsequent modulation of this pathway represent a substantial potential for innovative clinical interventions in the management of liver cancer.

Keywords: GSK-3β; PI3K/Akt pathway; liver cancer; regulatory mechanism; signal transduction.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Evaluation of the effect of GSK-3β on liver cancer based on the Pl3K/AKT pathway.
FIGURE 2
FIGURE 2
Activating GSK-3β promotes the occurrence of liver cancer.
FIGURE 3
FIGURE 3
Inhibiting GSK-3β inhibits the occurrence of liver cancer.
FIGURE 4
FIGURE 4
VOSviewer_PI3KAKT.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aaron M. H., Brendan D. M. (2021). Cancer signaling drives cancer metabolism: AKT and the Warburg effect. Cancer Res. 81, 4896–4898. 10.1158/0008-5472.CAN-21-2647 - DOI - PubMed
    1. A D., Kn S. (2020). The role of GSK3β in T lymphocytes in the tumor microenvironment. Front. Oncol. 10, 1221. 10.3389/fonc.2020.01221 - DOI - PMC - PubMed
    1. AL R., V S., E W., D S., T K., S L., et al. (2015). MiR-96-5p influences cellular growth and is associated with poor survival in colorectal cancer patients. Mol. Carcinog. 54 (11), 1442–1450. 10.1002/mc.22218 - DOI - PubMed
    1. Antonino G., Aaron Song Chuan F., Hiu Ying Julia L., Kenneth Chun-Yong Y., William J., Robert H. J., et al. (2023). PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Mol. Cancer 22, 138. 10.1186/s12943-023-01827-6 - DOI - PMC - PubMed
    1. A S. (2017). Chemoresistance in cancer cells: exosomes as potential regulators of therapeutic tumor heterogeneity. Nanomedicine Lond. Engl. 12 (17), 2137–2148. 10.2217/nnm-2017-0184 - DOI - PubMed

LinkOut - more resources